<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03951259</url>
  </required_header>
  <id_info>
    <org_study_id>SM934</org_study_id>
    <nct_id>NCT03951259</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of SM934 Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Safety and Efficacy of SM934 in Adult Subjects With Active Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu ZuoYou Medicine Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, double-blind, placebo-controlled, phase 2 study. The
      purpose of the study is to initially evaluate the safety and efficacy of SM934 combined with
      steroids compared to placebo in adult subjects with active systemic lupus erythematosus (SLE)
      over a 12-week period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 24, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects with Lupus Low Disease Activity Score (LLDAS) in each group</measure>
    <time_frame>Week 12</time_frame>
    <description>LLDAS is defined as meeting the following criteria:
SLEDAI-2K ≤4, with no activity in major organ systems (renal, CNS, cardiopulmonary, vasculitis), and no reported fever, hemolytic anemia, or gastrointestinal activity)
No new disease activity compared with the previous assessment (no new British isles lupus assessment group (BILAG) A domain score or no more than 1 new BILAG B domain score)
PGA ≤1 on a 0-3 scale visual visual analogue scale (VAS)
A current prednisone (or equivalent) dose of ≤7.5 mg daily
Well-tolerated standard maintenance doses of permitted immunosuppressive drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects with Systemic Lupus Erythematosus Responder Index - 4 (SRI-4) response in each group</measure>
    <time_frame>Week 12</time_frame>
    <description>SRI-4 response is defined as:
≥ 4-point reduction from baseline in SLEDAI-2K score
No new BILAG A and no more than 1 new BILAG B domain score
No worsening from baseline in the PGA (&lt;10% worsening from baseline).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects with Treatment-Emergent Adverse Events (TEAEs) in each group</measure>
    <time_frame>Baseline through Week 13</time_frame>
    <description>Percentage of Subjects with TEAEs in each group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change of SLEDAI-2000 and Physician Global Assessment (PGA) from baseline in each group</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage change of SLEDAI-2000 and PGA from baseline in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects with 30% improvement in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score in each group</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage of subjects who have at least 30% improvement in CLASI score compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of SLICC/ACR from baseline</measure>
    <time_frame>Week 12</time_frame>
    <description>Change of SLICC/ACR score from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects and number of days with steroids dose equal or less to prednisone 7.5mg per day</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage of subjects and number of days with steroids dose equal or less to prednisone 7.5mg per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with Proteinuria &lt; 0.5g/24h in each group</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage of subjects with 24hour urine protein level less than 0.5g in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change of complement 3 (C3) and complement 4 (C4) from baseline in each group</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage change of complement 3 (C3) and complement 4 (C4) from baseline in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change of anti-dsDNA level from baseline in each group</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage change of anti-dsDNA level from baseline in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to SLE flare and Percentage of subjects with SLE flare</measure>
    <time_frame>Baseline through week 12</time_frame>
    <description>SLE flare is defined as: Compared to baseline, one new BILAG A or more than 1 new BILAG B domain score. Time to SLE flare is defined as the date of SLE flare minus the date of treatment initiation plus one.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>SM934 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SM934 10mg（1 tablet）+Placebo（4 tablets）p.o. qd in combination with steroids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SM934 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SM934 10mg（3 tablet）+ Placebo（2 tablets）p.o. qd in combination with steroids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SM934 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SM934 10mg（5 tablet）p.o. qd in combination with steroids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo（5 tablets）p.o. qd in combination with steroids</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SM934</intervention_name>
    <description>In this study, the investigating intervention is oral administration of SM934. SM934 is a water-soluble derivative of arteminisin, which exerts immunosuppressive functions in vitro and in vivo.</description>
    <arm_group_label>SM934 10mg</arm_group_label>
    <arm_group_label>SM934 30mg</arm_group_label>
    <arm_group_label>SM934 50mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>The placebo pills are made identical to the investigating SM934 in appearance.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 to 70;

          -  Have a clinical diagnosis of SLE according to SLICC-2012 classification criteria;

          -  Have active SLE with SLEDAI-2k ≥ 6;

          -  Have positive anti-nuclear antibody (ANA) test results;

          -  Are on a stable steroids treatment (equals to prednison more than 7.5mg daily but no
             more than 0.5mg/kg/d) for SLE for at least 30 days prior to first dose of study agent;

          -  Females of childbearing age are willing to use appropriate contraception;

          -  Are voluntary to to provide and sign voluntary informed consent is given;

        Exclusion Criteria:

          -  Have any unstable or progressive manifestation of SLE, including but not limited to
             Central nervous system (CNS) involvement, transverse myelitis, systemic vasculitis,
             vasculitis with GI involvement, severe or rapidly progressive lupus nephritis, lupus
             nephritis with proteinuria &gt; 3g/24h, pulmonary hemorrhage, myocarditis;

          -  Have abnormal liver function test or renal function test: Alanine
             aminotransferase（ALT）or aspartate aminotransferase (AST) &gt;2 upper limit of normal
             (ULN); Gamma-glutamyl transferase (GGT) &gt;1.5 ULN; Creatinine or Blood urea nitrogen
             (BUN) &gt;1.5 ULN;

          -  Have a history of acute myocardiac infarction, unstable angina, severe arrhythmias
             within 6 months prior to first dose of study agent;

          -  Have any major illness/condition or evidence of an unstable clinical condition not due
             to SLE (eg, cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal,
             psychiatric), which, in the Investigator's judgment, will substantially increase the
             risk to the participant if he or she participates in the study;

          -  Have any acute or chronic infectious disease, which requires medical intervention;

          -  Have a history of cancer within the last 5 years, except for adequately treated skin
             cancer, or carcinoma in situ of the uterine cervix;

          -  Have a planned surgical procedure;

          -  Have received a biologic investigational agent in the past one year;

          -  Have received the following treatment within 30 days prior to first dose of study
             agent: live vaccine; change of glucocorticoids dose; IV, intra-muscular (IM),
             intra-articular (IA) administration of glucocorticoids; other
             immunosuppressants/immunomodulators; anti-malarial drugs; traditional medicines which
             has proved to be effective in SLE;

          -  Have had a major organ transplant;

          -  Have a history of HIV, or test positive at screening for HIV;

          -  Test positive for Hepatitis B virus (HBV)-DNA or Hepatitis C virus (HCV)-RNA;

          -  Have or have had a substance abuse (drug, alcohol) problem in the past one year;

          -  Are currently using or planned to use estrogen-containing contraceptive methods;

          -  Have enrolled in an investigational study within 3 months prior to first dose of study
             agent;

          -  Investigator considers candidates not appropriating for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nan Shen, MD &amp; PhD</last_name>
    <phone>+86-21-63260477</phone>
    <email>nanshensibs@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Huihua Ding, MD</last_name>
    <phone>+86-21-53882280</phone>
    <email>dinghuihua@outlook.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Rheumatology, RenJi Hospital, School of Medicine, Shanghai JiaoTong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nan Shen, MD &amp; PhD</last_name>
      <phone>+86-21-63260477</phone>
      <email>nanshensibs@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Huihua Ding, MD</last_name>
      <phone>+86-21-53882280</phone>
      <email>dinghuihua@outlook.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nan Shen, MD &amp; PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qiang Guo, MD &amp; PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Min Dai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Huihua Ding, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.sciencedirect.com/science/article/pii/S1567576909002781?via%3Dihub</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Hou LF, He SJ, Wang JX, Yang Y, Zhu FH, Zhou Y, He PL, Zhang Y, Yang YF, Li Y, Tang W, Zuo JP. SM934, a water-soluble derivative of arteminisin, exerts immunosuppressive functions in vitro and in vivo. Int Immunopharmacol. 2009 Dec;9(13-14):1509-17. doi: 10.1016/j.intimp.2009.09.003. Epub 2009 Sep 19.</citation>
    <PMID>19772931</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>May 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

